Mr. Matsubara has worked in the pharmaceutical industry for nearly 40 years.
He started his career as a Medical Representative at Yamanouchi in Japan, and worked in various positions such as Finance and Corporate Planning before being transferred in 2000 to Yamanouchi USA in New Jersey as VP in charge of Business Development. He was tasked with establishing a Sales and Marketing Organization to launch a product in the US marketplace and eventually became COO of Yamanouchi Pharma America.
After the merger of Fujisawa and Astellas in 2005, he moved to Chicago as Executive Vice President of Astellas USA. In 2006 he moved to Ireland as EVP of Astellas Ireland where he stayed until 2013.
He joined JPMA in January 2014 as Managing Director responsible for international affairs, Intellectual Property Right and Environmental issues.
He received his BA from Hitotsubashi University in 1977
Laurie J. Olson, Executive Vice President, Strategy, Portfolio and Commercial Operations, Pfizer
Laurie Olson is Executive Vice President of Strategy, Portfolio and Commercial Operations of Pfizer. She is responsible for overseeing the shaping of Pfizer’s longer-term strategy, supporting the execution for Pfizer’s commercial objectives, and providing portfolio advisory functions to guide R&D investment decisions. Laurie is a member of Pfizer’s Executive Leadership Team and also a member of the Portfolio Strategy Investment Committee, which oversees decisions regarding enterprise portfolio investment and advancement.
Laurie joined Pfizer in 1987 as an Analyst in the company’s Marketing Research organization. She has since held both U.S. and global leadership roles in marketing, commercial development, strategy, analytics and operations. In her most recent role as Senior Vice President, Portfolio Management and Analytics, she served on an executive task force that successfully redesigned Pfizer’s R&D organization to strengthen its pipeline and improve efficiency. In 2011, Corporate Strategy was added to her responsibilities.
In addition to her daily responsibilities, she is the executive sponsor of Pfizer’s global Lesbian, Gay, Bisexual, and Transgender Colleague Council and serves on the company’s worldwide Diversity Leadership Council.
Laurie earned a Bachelor of Science degree in Economics from the State University of New York at Stony Brook and an MBA in Marketing from Hofstra University.
Ramona Sequeira, President, United States Business Unit, Takeda
Ramona Sequeira is responsible for the company’s commercial operations in the U.S. She serves as a member of Takeda’s Executive Team.
Prior to joining Takeda, Ms. Sequeira held various senior roles of increasing responsibility at Eli Lilly, both in the U.S. and the U.K. During her career, she led several successful product launches, managed relationships with partners, improved operational performance and workforce engagement. In her role as General Manager, U.K. Hub, she had responsibility for all affiliate operations in the U.K., Republic of Ireland and Northern Europe. She was a member of the Association of the British Pharmaceutical Industry.
Ms. Sequeira is a member of the PhRMA Board of Directors. PhRMA is the Pharmaceutical Research and Manufacturers of America, representing the country’s leading biopharmaceutical researchers and biotechnology companies. Additionally, Ms. Sequeira is a board member of the Healthcare Leadership Council, a coalition of executives from all disciplines within American healthcare. It is the exclusive forum for the nation’s healthcare leaders to jointly develop policies, plans, and programs to achieve their vision of a 21st century system that makes affordable, high-quality care accessible to all Americans.
Ms. Sequeira received a B.S. with honors in molecular genetics and molecular biology from the University of Toronto, and later received an MBA from McMaster University in Canada.
Nobuhiko Tamura, Vice Chair and President, Sunovion Pharmaceuticals Inc.
Nobuhiko Tamura is Sunovion’s champion of drug discovery and development and primary architect of the R&D that fuels the company’s dynamic discovery and development efforts.
He was appointed President in November 2014, after assuming the executive leadership role as Sunovion Vice Chair, Board of Directors in April 2014. Mr. Tamura also serves as a Senior Executive Officer of Sumitomo Dainippon Pharma Co., Ltd. Group, the parent company of Sunovion.
Previously, as Chief Scientific Officer of Sunovion, Mr. Tamura led the submission to the FDA of Latuda (lurasidone HCl), an atypical antipsychotic approved in 2010 for the treatment of schizophrenia in adults. He was the President of Dainippon Sumitomo Pharma America (DSPA) prior to the acquisition of Sepracor Inc.
Mr. Tamura began his career as a researcher at Sumitomo Chemical Co., Ltd. and was one of the first employees of Sumitomo Pharmaceutical Co., Ltd. (SP), which was created in 1984. After six years in SP’s discovery lab, he worked in the business development group in New York and served as the company’s US representative. From 1994 to 2007, he led multiple chemical and biological projects in the R&D Division of SP and Sumitomo Dainippon Pharma, and fostered the development of new chemical entities for the treatment of central nervous system diseases and other disorders.
Mr. Tamura serves on the Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA).
Mr. Tamura earned his master’s degree in pharmacy from Tohoku University and his bachelor’s degree in pharmacy from the Tokyo University of Science.
Ed Saltzman, President and Founder, Defined Health
Ed is President and Founder of Defined Health. He possesses a vast knowledge of the pharmaceutical and biotechnology industry accumulated over Defined Health’s 27 years of consultancy to pharma, biotech, specialty pharma and investors. From this unique perspective, he manages business development and disease area strategy projects and also provides guidance on most of Defined Health’s project work.
Prior to founding Defined Health, Ed held positions at the Ayerst Laboratories unit of American Home Products, where he had responsibility for evaluation and forecasting of compounds being considered for licensing, and at FIND/SVP, where he managed the Healthcare Information Center.
Ed is a well-regarded and in-demand speaker on industry issues. He has spoken over the past 10 years to large audiences at Defined Health’s Therapeutic Insight conferences, the Licensing Executives Society Annual Meeting and various industry conferences. In addition to these public events, Ed has presented targeted strategy briefings and held discussions privately with scores of boards of directors, executive management committees and licensing and business development teams at large pharma, specialty pharma and biotech companies.
Ed is a member of the Licensing Executives Society and the New York Pharma Forum and is a graduate of New York University.